Osborn Williams & Donohoe LLC reduced its stake in shares of Pfizer Inc. (NYSE:PFE) by 1.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 121,480 shares of the biopharmaceutical company’s stock after selling 2,042 shares during the quarter. Osborn Williams & Donohoe LLC’s holdings in Pfizer were worth $4,337,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in PFE. Altfest L J & Co. Inc. grew its position in Pfizer by 67.0% during the 2nd quarter. Altfest L J & Co. Inc. now owns 107,278 shares of the biopharmaceutical company’s stock worth $3,603,000 after purchasing an additional 43,024 shares during the last quarter. HL Financial Services LLC grew its position in Pfizer by 1.1% during the 2nd quarter. HL Financial Services LLC now owns 3,222,985 shares of the biopharmaceutical company’s stock worth $108,260,000 after purchasing an additional 35,744 shares during the last quarter. Sphera Funds Management LTD. purchased a new position in Pfizer during the 1st quarter worth $13,342,000. Searle & CO. grew its position in Pfizer by 92.7% during the 1st quarter. Searle & CO. now owns 80,052 shares of the biopharmaceutical company’s stock worth $2,739,000 after purchasing an additional 38,500 shares during the last quarter. Finally, Hartford Financial Management Inc. grew its position in Pfizer by 10.8% during the 2nd quarter. Hartford Financial Management Inc. now owns 8,538 shares of the biopharmaceutical company’s stock worth $286,000 after purchasing an additional 835 shares during the last quarter. Hedge funds and other institutional investors own 69.89% of the company’s stock.

Several brokerages have issued reports on PFE. Zacks Investment Research raised shares of Pfizer from a “hold” rating to a “buy” rating and set a $40.00 price objective on the stock in a research report on Tuesday, October 3rd. Vetr downgraded shares of Pfizer from a “buy” rating to a “hold” rating and set a $35.71 price objective on the stock. in a research report on Wednesday, September 13th. BMO Capital Markets set a $39.00 price objective on shares of Pfizer and gave the stock a “buy” rating in a research report on Tuesday, October 31st. Sanford C. Bernstein set a $39.00 price objective on shares of Pfizer and gave the stock a “buy” rating in a research report on Tuesday, September 19th. Finally, Deutsche Bank set a $38.00 price objective on shares of Pfizer and gave the stock a “buy” rating in a research report on Wednesday, December 6th. Two analysts have rated the stock with a sell rating, six have assigned a hold rating and thirteen have assigned a buy rating to the company’s stock. Pfizer has a consensus rating of “Buy” and a consensus target price of $38.77.

In related news, EVP Alexander R. Mackenzie sold 7,350 shares of the business’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $35.65, for a total transaction of $262,027.50. Following the sale, the executive vice president now owns 117,432 shares of the company’s stock, valued at $4,186,450.80. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Alexander R. Mackenzie sold 14,700 shares of the business’s stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $35.30, for a total transaction of $518,910.00. Following the sale, the insider now directly owns 117,432 shares in the company, valued at approximately $4,145,349.60. The disclosure for this sale can be found here. 0.06% of the stock is owned by insiders.

Shares of Pfizer Inc. (NYSE:PFE) opened at $37.20 on Monday. The firm has a market cap of $221,708.50, a PE ratio of 14.88, a PEG ratio of 2.62 and a beta of 1.01. The company has a quick ratio of 1.15, a current ratio of 1.43 and a debt-to-equity ratio of 0.56. Pfizer Inc. has a fifty-two week low of $30.90 and a fifty-two week high of $37.22.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.65 by $0.02. The business had revenue of $13.17 billion for the quarter, compared to the consensus estimate of $13.17 billion. Pfizer had a net margin of 18.69% and a return on equity of 25.41%. The business’s quarterly revenue was up .9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.61 earnings per share. sell-side analysts expect that Pfizer Inc. will post 2.59 EPS for the current year.

The company also recently announced a quarterly dividend, which was paid on Friday, December 1st. Stockholders of record on Friday, November 10th were issued a $0.32 dividend. This represents a $1.28 annualized dividend and a dividend yield of 3.44%. The ex-dividend date of this dividend was Thursday, November 9th. Pfizer’s payout ratio is 79.01%.

COPYRIGHT VIOLATION WARNING: This news story was first published by Watch List News and is the property of of Watch List News. If you are viewing this news story on another publication, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this news story can be viewed at https://www.watchlistnews.com/pfizer-inc-pfe-shares-sold-by-osborn-williams-donohoe-llc/1771166.html.

Pfizer Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.